VEGFA and age-related macular degeneration: Aflibercept (Eylea) was developed by Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA) with the intention of creating a therapeutic for exudative AMD with sustained inhibitory effects against VEGF [85].